FDA Delays Actos Combo Drug Review as Actos Bladder Cancer Lawsuits Continue to Mount
The FDA did not specify why the review, which was originally scheduled for January 25th 2012, was pushed back until April. The federal regulatory agency has been conducting an going safety review of Actos since 2010, when scientific research indicated that use of the drug may potentially lead to an increased risk for developing bladder cancer. In June 2011, the FDA issued new safety warnings advising Actos users that the bladder cancer risk was greatest among those individuals taking the drug for one year or longer.
Actos is currently one of the biggest moneymakers for Takeda Pharmaceuticals, generating nearly $5 billion in revenue in 2010 alone. The drug’s patent is expected to expire next year, leaving other drug manufacturers free to develop generic versions of Actos. The outcome of the pending litigation, however, may have a significant impact on the future sale of the drug.
There are currently an estimated 4,000 lawsuits filed in state and federal courts across the country on behalf of Actos users and their families who claim that the drug caused bladder cancer and other serious side effects. Attorneys for the plaintiffs and Takeda are currently working to have the suits consolidated into a multidistrict litigation in federal court for pretrial purposes.
The FDA says it will continue to monitor the safety of Actos in the U.S. The drug has already been recalled in both France and Germany, despite the European Medical Agency’s stance that Actos is still a suitable treatment for diabetes patients for whom other methods have proven ineffective.
National law firm Nadrich & Cohen is currently investigating Actos users in all 50 states who experienced serious side effects after taking the drug. The firm has created an online resource center at www.SideEffectActos.com to provide the latest news, updates and information to concerned Actos users. Free initial case evaluations are available by calling the Injury Hotline at 1-800-722-0765 or by visiting www.SideEffectActos.com.
If you or a loved one has developed bladder cancer after taking Actos, the law firm of Nadrich & Cohen urges you to contact them today to discuss your claim. All cases are accepted on a contingency basis, meaning there is never a fee unless a judgment is recovered on your behalf.
National Client Intake Coordinator
Nadrich & Cohen LLP
12100 Wilshire Blvd. Suite 1250
Los Angeles, CA 90025
Nadrich & Cohen LLP is a national law firm specializing in assisting clients who've been injured by defective medical devices, harmful prescription drugs, car accidents, motorcycle accidents, bicycle accidents and dog bites.
Nadrich & Cohen LLP
12100 Wilshire Blvd
Los Angeles, CA 90025
National Client Intake Coordinator
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release FDA Delays Actos Combo Drug Review as Actos Bladder Cancer Lawsuits Continue to Mount here
News-ID: 203655 • Views: 4294
More Releases from Nadrich & Cohen LLP
Yaz Lawsuit Settlements Reach $142 Million
Nadrich & Cohen, LLP reports that Bayer is continuing to offer settlements to plaintiffs involved in federal Yaz side effects litigation. Los Angeles, CA, April 27, 2012 – Nadrich & Cohen, LLP reports that German drug-maker Bayer AG has settled approximately 651 Yaz side effects lawsuits totaling $142 million. Earlier this month, it was reported that the drug-maker had reached settlements in approximately 500 cases filed by women who claimed
Yaz, Yasmin to Get New Labels as FDA Warns of Blood Clot Risk
Nadrich & Cohen, LLP reports that Yaz and similar birth control pills are to receive updated warning labels advising patients of the risk for developing serious blood clots. Los Angeles, CA, April 10, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has ordered Bayer to produce new warning labels for several of its oral contraceptives, including Yaz, Yasmin and Beyaz.
FDA Schedules Advisory Panel Meeting to Discuss Metal Hip Safety
Nadrich & Cohen, LLP reports that the FDA has scheduled an advisory panel to discuss the safety of metal hip implants. Los Angeles, CA, March 29, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has a scheduled an advisory panel meeting to discuss the safety of metal hip implants and all-metal hip resurfacing systems. The two-day panel, which is expected
Pradaxa Side Effects Lawsuits Filed in Federal Court
Nadrich & Cohen, LLP reports that three Pradaxa side effects lawsuits have been filed in federal courts across the country. Los Angeles, CA, March 7, 2012 – National law firm Nadrich & Cohen, LLP has learned that three Pradaxa side effects lawsuits have been filed against Boehringer Ingelheim, the drug’s manufacturer. The cases were filed in federal district courts located in Tennessee, Kentucky and Louisiana and it’s believed they are the
More Releases for Actos
Nadrich & Cohen LLP Clarifies Statements Regarding Actos Bladder Cancer Lawsuits
Los Angeles, CA, January 24, 2012 – National law firm Nadrich & Cohen LLP would like to clarify previous statements regarding the pending Actos bladder cancer litigation. Earlier press releases included incorrect information regarding the total number of Actos lawsuits filed against the drug’s manufacturer, Takeda Pharmaceuticals. Those releases, based on media reports, estimated the number of lawsuits filed in state and federal courts nationwide in connection with Actos numbered
Federal Panel Votes to Consolidate Actos Bladder Cancer Lawsuits
Nadrich & Cohen LLP reports that a federal judicial panel has voted to consolidate pending Actos bladder cancer claims into a multidistrict litigation for pretrial proceedings. Los Angeles, CA, January 5, 2012 – Plaintiffs in the Actos bladder cancer litigation have successfully moved to have the federal lawsuits consolidated into a multidistrict litigation for pretrial proceedings. The cases will be transferred to the Western District Court of Louisiana, with the
More Actos Bladder Cancer Lawsuits Filed in Los Angeles
Nadrich & Cohen LLP reports that new lawsuits have been filed in Los Angeles against the maker of Actos by two patients who allege the drug caused bladder cancer. Los Angeles, CA, December 30, 2011 – As Takeda Pharmaceuticals continues to battle litigation over its Type 2 diabetes drug Actos, three additional lawsuits were filed in a Los Angeles court. The newest claims join the thousands of other Actos lawsuits that
Nadrich & Cohen Now Reviewing Actos Bladder Cancer Claims
Los Angeles, CA, December 12, 2011 – Nadrich & Cohen LLP, a prominent national law firm, is now reviewing claims from Actos users in all 50 states who developed bladder cancer after taking the drug. In an effort to connect with even more Actos users across the country, the firm has established an online resource center at www.SideEffectActos.com. Actos was approved by the U.S. Food and Drug Administration to treat adults
Actos Bladder Cancer Lawsuits Expected to Top 10,000
Los Angeles, CA, December 2, 2011 --- The number of lawsuits stemming from Actos bladder cancer claims may reach more than 10,000, according to a Bloomberg report. In response, national law firm Nadrich & Cohen, LLP has launched a new Actos bladder cancer resource website to assist patients in filing their claims. Visitors to www.SideEffectActos.com can read up on the link between Actos and bladder cancer, get the latest updates
Actos Bladder Cancer Link Has More Patients Seeking Legal Help
Los Angeles, CA, November 28, 2011 – As more Actos users are discovering the link between the Type 2 diabetes drug and bladder cancer, the need for experienced legal representation has increased. Prominent national law firm Nadrich & Cohen, LLP is now offering free initial case evaluations for Actos users who’ve experienced serious side effects, including bladder cancer. The U.S. Food and Drug Administration issued the first warnings about possible